Abstract
BackgroundThe efficacy and safety of Upadacitinib (UPA), a selective Janus kinase inhibitor, have been evaluated in the SELECT clinical trial program [1-6]. The UPwArds study was designed to further elucidate...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
